Table 1.
Demographic, clinical, and histologic characteristics of the patients and biopsies included
| Cohort Characteristics | Total (n=936) |
|---|---|
| Donor demographics | |
| Donor type, N (%) | |
| Donation after brain death | 726 (77.6) |
| Donation after cardiac death | 153 (16.3) |
| Living donation, N (%) | 57 (6.1) |
| Age (yr), mean±SD | 47.7±14.7 |
| Male, N (%) | 497 (53.1) |
| Diabetes, N (%) | 24 (2.6) |
| Recipient demographics | |
| Age (yr), mean±SD | 53.5±13.3 |
| Male, N (%) | 572 (61.1) |
| Ethnicity, N (%) | |
| Caucasian | 920 (92.3) |
| African | 12 (1.3) |
| Asian | 3 (0.3) |
| Hispanic | 1 (0.1) |
| BMI (kg/m2), mean (range) | 25.4 (4.5) |
| Pre-transplant donor-specific HLA antibodies, N (%) | 408 (11.6%) |
| Repeat transplantation, N (%) | 141 (15) |
| Cold ischemia time (h), mean±SD | 14.2±5.7 |
| Total number of HLA A/B/DR mismatches, mean±SD | 2.8 (1.3) |
| Biopsy characteristics | Total (n=3510) |
| Banff 2019 diagnosis, N (%) | |
| No rejection | 2671 (76.1) |
| Borderline changes | 333 (9.5) |
| TCMR | 314 (8.9) |
| ABMR | 110 (3.1) |
| Mixed rejection (ABMR + TCMR) | 61 (1.7) |
| Mixed borderline rejection (ABMR + borderline changes) | 21 (0.6) |
| Indication biopsies, N (%) | n=773 (22.0) |
| Days since transplantation, median (interquartile range) | 22 (8–96) |
| eGFR at d of biopsy, median (interquartile range) | 19.8 (10.9–29.0) |
| Protocol biopsies, N (%) | n=2737 (78.0) |
| 3 mo | 823 (30.1) |
| 12 mo | 759 (27.7) |
| 24 mo | 639 (23.3) |
| 36 mo | 205 (7.5) |
| 48 mo | 22 (0.8) |
| 60 mo | 289 (7.6) |
| Days since transplant, median (interquartile range) | 377 (100–752) |
| eGFR at d of biopsy, median (interquartile range) | 46.4 (36.5–57.8) |